肌肉骨骼疼痛：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 預計西班牙肌肉骨骼疼痛市場將從2025年的4.1億美元成長到2035年的7.3億美元。
• 以下因素推動市場成長：
• 慢性肌肉骨骼疾病的日益普遍和人口老化。
• 擴大採用新型非鴉片類和標靶疼痛管理療法。
• 未來的成長取決於更安全、更有效的長期治療方法的研發。

肌肉骨骼疼痛概述

肌肉骨骼疼痛是全球最常見的疼痛類型，涵蓋源自骨骼、關節、肌肉和結締組織的急性和慢性疼痛。其病因包括傷害性疼痛、神經病變和傷害性可塑性通路，其發作和慢性化程度受生物心理社會因素的強烈影響，例如睡眠障礙、心理壓力和應對策略。診斷主要依靠臨床檢查，包括身體檢查、檢驗的後續觀察工具和針對性影像學檢查。現代治療優先考慮積極干預，例如個人化運動和物理治療，而非被動療法。標準藥物治療以非類固醇消炎劑（NSAIDs）和duloxetine為基準，並結合突破性的新型精準療法。對於廣泛的傷害性疼痛，例如纖維肌痛，可使用新近獲批的舌下服cyclobenzaprine進行治療。對於急性創傷和嚴重肌肉骨骼損傷，新型非依賴性周邊鈉通道抑制劑suzetrigine透過減少鴉片類藥物依賴，改變臨床工作流程。為解決中樞敏化問題，採用認知行為療法和疼痛神經科學教育，而介入治療則僅限於非常具體的結構性病因。早期賦能患者對於最大限度地提高長期功能恢復和改善生活品質非常重要。

主要亮點

• 根據預測，德國肌肉骨骼疼痛患者人數將從2025年的12,474,885 人增加到2035年的13,112,853 人。
• 肌肉骨骼疼痛是全球慢性疼痛、殘疾和生活品質下降的主要原因之一。
• 目前的治療方法主要目的是緩解症狀，許多患者仍然遭受持續性疼痛的困擾。
• 目前仍有大量未被滿足的需求，即需要治療以改善功能和活動能力，同時實現長期疼痛管理。

市場概覽

• 預計西班牙肌肉骨骼疼痛市場將從2025年的4.1億美元成長到2035年的7.3億美元。
• 以下因素推動市場成長：
• 慢性肌肉骨骼疾病的日益普遍和人口老化。
• 擴大採用新型非鴉片類和標靶疼痛管理療法。
• 未來的成長取決於更安全、更有效的長期治療方法的研發。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Musculoskeletal Pain Market Outlook

Thelansis's "Global Musculoskeletal Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Musculoskeletal Pain treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Musculoskeletal Pain Overview

Musculoskeletal pain is the most prevalent pain category globally, encompassing acute and chronic conditions arising from bones, joints, muscles, and connective tissues. Driven by nociceptive, neuropathic, and nociplastic pathways, its development and chronicity are heavily influenced by biopsychosocial elements like sleep disruption, psychological distress, and coping strategies. Diagnosis is primarily clinical, guided by physical examination, validated tracking tools, and targeted imaging. Modern management prioritizes active interventions like tailored exercise and physiotherapy over passive treatment. Standard pharmacological care combines baseline non-steroidal anti-inflammatory drugs and duloxetine with landmark new precision therapeutics. For widespread nociplastic pain like fibromyalgia, management includes newly approved sublingual cyclobenzaprine. For acute trauma or severe musculoskeletal injury, the clinical workflow is transformed by suzetrigine, a novel non-addictive peripheral sodium channel inhibitor that reduces reliance on opioids. Cognitive behavioral therapy and pain neuroscience education are leveraged to address central sensitization, while interventional procedures are reserved for highly selective structural causes. Early patient empowerment is critical to maximize long-term functional recovery and enhance quality of life.

Key Highlights

• In Germany, the prevalent Musculoskeletal Pain population is projected to increase from 12,474,885 in 2025 to 13,112,853 by 2035.
• Musculoskeletal Pain is a leading cause of chronic pain, disability, and reduced quality of life worldwide.
• Current treatment options primarily provide symptomatic relief, with many patients experiencing persistent pain.
• Significant unmet need remains for therapies that provide long-term pain control while improving function and mobility.

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Ea

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)